(Q34078523)

30 July 2017

1 reference

title

Review article: potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease (English)

1 reference

inflammatory bowel diseases

30 July 2017

0 references

0 references

1 reference

Papa A

1

1 reference

30 July 2017

Danese S

series ordinal

2

1 reference

30 July 2017

Gasbarrini A

series ordinal

3

1 reference

30 July 2017

Gasbarrini G

series ordinal

4

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 November 2000

1 reference

Alimentary Pharmacology & Therapeutics

30 July 2017

1 reference

30 July 2017

14

1 reference

30 July 2017

11

1 reference

30 July 2017

1403-1409

1 reference

Early mucosal changes in Crohn's disease

30 July 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00860.X

Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00860.X

Inherited disorders of coagulation appear to protect against inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00860.X

Thrombotic vascular risk factors in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00860.X

Thromboembolism in inflammatory bowel disease: role of platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00860.X

Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00860.X

Treatment of corticosteroid-resistant ulcerative colitis with heparin--a report of 16 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00860.X

Pharmacodynamics, clinical indications, and adverse effects of heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00860.X

Inflammatory bowel disease and osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00860.X

Low molecular weight heparin as adjuvant therapy in active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00860.X

'Sticky' neutrophils, pathergic arthritis, and response to heparin in pyoderma gangrenosum complicating ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00860.X

Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00860.X

Heparin and heparan sulphate are inhibitors of human leucocyte elastase

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00860.X

Therapeutic uses of heparin beyond its traditional role as an anticoagulant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00860.X

Serum basic fibroblast growth factor in pediatric Crohn's disease. Implications for wound healing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00860.X

Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00860.X

A dual receptor system is required for basic fibroblast growth factor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00860.X

Heparin, cell adhesion, and pathogenesis of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00860.X

Cytokines in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00860.X

On the binding of tumor necrosis factor (TNF) to heparin and the release in vivo of the TNF-binding protein I by heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00860.X

Regulation of interleukin-8 binding and function by heparin and alpha2-macroglobulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00860.X

Is nitric oxide and heparin treatment justified in inflammatory bowel disease? An experimental study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00860.X

Heparin and low molecular weight heparin decrease nitric oxide production by human polymorphonuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00860.X

Heparin inhibits reactive oxygen species generation by polymorphonuclear and mononuclear leucocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00860.X

Inhibition of superoxide production in human neutrophils by combinations of heparin and thrombolytic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00860.X

Location of superoxide anion generation in human colonic mucosa obtained by biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00860.X

Thrombin stimulates the adherence of neutrophils to human endothelial cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00860.X

10.1046/J.1365-2036.2000.00860.X

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference